| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Multiple targets: antioxidant enzymes; inflammatory mediators (COX-2, TNF-α, IL-6); cancer-related targets (apoptosis pathways, cell cycle regulators).
|
|---|---|
| ln Vitro |
Kaempferol-7,4'-dimethyl ether exhibits antioxidant activity by scavenging free radicals and upregulating antioxidant enzyme expression. It has anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines such as TNF-α, IL-6, and COX-2. The compound shows anticancer activity by inducing apoptosis, inhibiting cell proliferation, and modulating cell cycle progression in various cancer cell lines. It may also have neuroprotective and cardioprotective properties.
|
| ln Vivo |
In vivo studies of kaempferol-7,4'-dimethyl ether are limited. Based on related kaempferol derivatives, it is expected to exhibit anti-inflammatory, antioxidant, and anticancer effects in animal models. Potential applications include: anti-inflammatory effects in models of acute and chronic inflammation; anticancer effects in tumor xenograft models; and neuroprotective effects in models of neurodegenerative diseases. Further studies are needed to characterize its specific in vivo activities.
|
| Enzyme Assay |
Antioxidant activity is assessed using standard assays such as DPPH radical scavenging, ABTS, FRAP, and ORAC. Anti-inflammatory activity is measured by inhibition of COX-2, LOX, or cytokine production in enzyme assays or cell-based systems. Anticancer activity is assessed by cell viability assays (MTT, SRB) and apoptosis assays (Annexin V/PI staining, caspase activity) using cancer cell lines. Enzyme inhibition studies use purified enzymes and spectrophotometric detection.
|
| Cell Assay |
Cancer cell lines (e.g., MCF-7, HeLa, A549) are cultured and treated with kaempferol-7,4'-dimethyl ether at various concentrations. Cell viability is measured by MTT or SRB assays. Apoptosis is assessed by flow cytometry using Annexin V/PI staining. Cell cycle analysis is performed by propidium iodide staining and flow cytometry. For anti-inflammatory studies, macrophage cell lines (e.g., RAW 264.7) are stimulated with LPS and cytokine levels are measured by ELISA.
|
| Animal Protocol |
In vivo studies for kaempferol-7,4'-dimethyl ether are limited in the published literature. Potential animal models include: carrageenan-induced paw edema or xylene-induced ear edema for anti-inflammatory evaluation; tumor xenograft models (e.g., in nude mice) for anticancer evaluation; and DSS-induced colitis models for inflammatory bowel disease. Standard protocols for these models involve administration of the compound (oral, intraperitoneal, or intravenous) followed by measurement of relevant endpoints.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for kaempferol-7,4'-dimethyl ether are limited. As a flavonoid, it is expected to be absorbed after oral administration, undergo extensive metabolism (including demethylation, glucuronidation, and sulfation), and be eliminated in urine and bile. The presence of methoxy groups may affect its metabolic stability and bioavailability compared to kaempferol. Standard laboratory storage conditions apply.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for kaempferol-7,4'-dimethyl ether are limited. Flavonoids are generally considered to have low toxicity. High doses may cause adverse effects, but comprehensive toxicity studies for this specific compound have not been reported. Standard laboratory safety practices should be followed when handling this compound. It is intended for research use only.
|
| References |
|
| Additional Infomation |
7,4'-Dimethylkaempferol is a dimethoxyflavonoid, a compound formed by replacing the 4' and 7' hydroxyl groups of kaempferol with methoxy groups. It is a component of propolis and has been isolated from various plants, including birch (Betula exilis), ginger (Zingiber mekongense), and galangal (Alpinia flabellata). It possesses antioxidant and plant metabolism-enhancing properties. It is a dimethoxyflavonoid, a dihydroxyflavonoid, belonging to the flavonol class of compounds. Its function is related to kaempferol. It is the conjugate acid of 7,4'-O-dimethylkaempferol-3-ol salt. 3,5-Dihydroxy-7-methoxy-2-(4-methoxyphenyl)-4H-chromen-4-one has been reported in Spiranthes vernalis, Aleuritopteris formosana, and other organisms with relevant data.
Kaempferol-7,4'-dimethyl ether is a naturally occurring flavonoid found in various plant species. It is a dimethylated derivative of kaempferol with methoxy substitutions at the 7 and 4' positions. The compound is used as a reference standard for the identification and quantification of flavonoid compounds in plant extracts and dietary supplements. Its biological activities, including antioxidant, anti-inflammatory, and anticancer properties, make it a compound of interest for pharmacological research. It is for research use only. |
| Molecular Formula |
C17H14O6
|
|---|---|
| Molecular Weight |
314.28946
|
| Exact Mass |
314.079
|
| CAS # |
15486-33-6
|
| PubChem CID |
5378823
|
| Appearance |
Light yellow to yellow solid
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
539.4±50.0 °C at 760 mmHg
|
| Flash Point |
201.7±23.6 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.656
|
| LogP |
2.5
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
23
|
| Complexity |
480
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC=C(C=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)OC)O)O
|
| InChi Key |
KZBAXKKOXPLOBX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H14O6/c1-21-10-5-3-9(4-6-10)17-16(20)15(19)14-12(18)7-11(22-2)8-13(14)23-17/h3-8,18,20H,1-2H3
|
| Chemical Name |
3,5-dihydroxy-7-methoxy-2-(4-methoxyphenyl)chromen-4-one
|
| Synonyms |
Kaempferol-7,4'-dimethyl ether
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1818 mL | 15.9089 mL | 31.8177 mL | |
| 5 mM | 0.6364 mL | 3.1818 mL | 6.3635 mL | |
| 10 mM | 0.3182 mL | 1.5909 mL | 3.1818 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
